Display Settings:

Format

Send to:

Choose Destination
Neuro Oncol. 2010 Sep;12(9):908-16. doi: 10.1093/neuonc/noq049. Epub 2010 May 25.

Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.

Author information

  • 1UCSF/UCB Joint Graduate Group in Bioengineering, Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, California 94158-2330, USA. inas.khayal@radiology.ucsf.edu

Abstract

The purpose of this study was to evaluate diffusion parameters at pre-, mid-, and post-radiation therapy (RT) in contrast-enhancing and nonenhancing lesions of postsurgical glioblastoma multiforme patients treated with the standard of care RT concurrently with temozolomide (TMZ) followed by adjuvant TMZ and an antiangiogenic drug. The diffusion parameters explored include baseline and short-term changes in apparent diffusion coefficient, fractional anisotropy, and eigenvalues. These diffusion parameters were examined as early markers for disease progression by relating them to clinical outcome of 6-month progression-free survival. The results indicated that changes from mid- to post-RT were significantly different between patients who progressed within 6 months vs those who were free of progression for 6 months after initiation of therapy. The study also showed that the changes in diffusion parameters from the mid- to post-RT scan may be more significant than those from pre- to mid-RT and pre- to post-RT. This is important because the mid-RT scan is currently not performed as part of the standard clinical care.

PMID:
20501631
[PubMed - indexed for MEDLINE]
PMCID:
PMC2940691
Free PMC Article

Images from this publication.See all images (3)Free text

Fig. 1.
Fig. 2.
Fig. 3.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk